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Abstract
Objective
In patients with postoperative recurrence of Crohn’s disease endoscopic and clinical remis-
sion can be maintained for up to 1 year with low infliximab doses (3 mg/Kg). However, in the-
ory low-dose infliximab treated patients could develop subtherapeutic trough levels,
infiximab antibodies, and might loose response to therapy. To verify this hypothesis inflixi-
mab pharmacokinetics and clinical/endoscopic response were checked in a group of
patients treated in the long term with low infliximab doses.
Design
Infliximab antibodies, infliximab levels, highly-sensitive CRP and fecal calprotectin were
measured during the 8-week interval in 5 consecutive patients in clinical (Crohn’s Disease
Activity Index < 150) and endoscopic (Rutgeerts scores 0–1) remission after one year of
therapy with infliximab 3 mg/Kg. For comparison with reported standards, infliximab phar-
macokinetics and inflammatory parameters were also tested in 6 Crohn’s disease patients
who did not undergo surgery and who were in clinical remission while on infliximab 5 mg/
Kg. Patients on low infliximab dose also underwent colonoscopy after 18 additional months
of therapy.
Results
Highly sensitive CRP and fecal calprotectin increased in all patients during the 8-week inter-
val. Infliximab trough levels were lower in patients treated with the low dose compared to
controls (mean±SE: 2.0±0.3 vs 4.75±0.83 μg/mL respectively p<0.05). Infliximab antibodies
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were present in two of the subjects treated with low infliximab dose and in none of the con-
trols. However, in low dose-treated patients after 18 additional months of therapy endos-
copy continued to show mucosal remission and none of them developed clinical recurrence
or side effects.
Conclusions
Patients treated with low infliximab doses had lower trough levels compared to patients
treated with 5 mg/Kg and some developed antibodies to infliximab. However, low infliximab
doses sustained clinical and endoscopic remission for a total of 30 months of treatment.
Introduction
Since 2006, the monoclonal anti-TNF-α antibodies infliximab and adalimumab have been
shown in several studies to be highly effective in preventing post-operative recurrence [POR]
of Crohn’s disease [CD] [1]. Initial studies from our group showed that maintenance inflixi-
mab is effective in preventing POR in the long term [2]–a finding recently confirmed by others
[3]. However—as in patients who have not undergone surgery—the long-term management of
CD patients with biologics after surgery incurs significant costs and safety risks [4–9]. Stopping
infliximab has been proposed by some authors [10,11] however this is followed by prompt
endoscopic disease relapse [2], eventually leading to clinical recurrence [3]. To address this
issue, we proposed in a pilot study a dose titration strategy, with the goal of finding the minimal
effective dose of infliximab in patients with endoscopic recurrence after surgery [2]. We
showed that a dose of 3 mg/Kg was capable of inducing and maintaining endoscopic and clini-
cal remission for up to 1 year in all patients [2].
A theoretical issue in adopting a low dose strategy in the long term is the formation of anti-
bodies to infliximab [ATI]—as a result of low infliximab trough levels [ITL]—an event that
could also lead to loss of response and/or infusion reactions [12–14]. The generally accepted
therapeutic threshold for ITL has been reported to be3 μg/mL [12, 15, 16].
The goal of the present study was to clarify this issue and provide extended follow-up data
on patients maintained on low-dose infliximab to prevent POR. For this purpose we measured
ITL, ATI as well as markers of disease activity in 5 consecutively selected patients with proven
POR maintained in clinical and endoscopic remission with 3 mg/kg doses of infliximab for one
year. To compare results with those reported in the literature for standard infliximab doses
[12,15], ITL, ATI and inflammation markers were also measured in 6 controls (CD patients
who did not undergo surgery and in clinical remission treated with infliximab 5 mg/Kg).
Methods
Study design
Five of the ten patients subjected to the dose titration study [2] were consecutively enrolled to
participate in the current study (Fig 1). They all presented endoscopic relapse when the stan-
dard dose (5 mg/Kg) infliximab—initiated immediately after surgery and continued for 3 years
—was stopped for 4 months [2]. Mucosal healing was then re-induced with 3 mg/Kg infliximab
[2]. When enrolled in the current study they were all in clinical (Crohn’s Disease Activity
Index [CDAI]< 150) [17] and endoscopic remission (Rutgeerts score 0–1) [18] after one year
of infliximab treatment at 3 mg/Kg. Individual Rutgeerts scores at enrollment were 0,1,1,1,0 in
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the patients progressively numbered 1–5 (Table 1). Solely for the purpose to compare ITL, ATI
and inflammatory markers in our study with those reported in the literature using standard
infliximab doses [12,15] six controls (CD patients in clinical remission [CDAI< 150] who did
not undergo surgery) treated with 5 mg/Kg were also included in the study. None of the study
subjects and the controls were concomitantly treated with immunomodulators. All patients
were asked to provide a stool sample at weeks 4 and 8 of the 8-week infliximab therapeutic
interval for the measurement of fecal calprotectin [FC], performed by a commercially available
ELISA test (Calprest, Eurospital, Trieste-Italy) after protein extraction on a weighted stool sam-
ple. Blood was taken immediately before, immediately after the infusion and at 4 weeks. In
these samples, infliximab concentrations and ATI were measured by homogenous mobility
shift assay [19], with limits of detection of 0.91 μg/mL and 3.13 U/mL respectively—while
highly sensitive CRP [HS-CRP] was measured by proprietary methods (Prometheus Laborato-
ries Inc, San Diego, CA). These tests were performed during at least three consecutive 8-week
therapeutic intervals within the same time frame for all the patients. All the five study subjects
on low infliximab doses (but none of the controls) were followed clinically every 6 months and
were subjected to colonoscopy after 18 additional months of therapy. The other five patients
on low infliximab dose from the original titration study (2) were only followed clinically for an
additional 12 months.
Fig 1. Study Design. Patients subjected to prophylactic infliximab [IFX] 5 mg/Kg after surgery and in full
remission after 3 years of therapy showed endoscopic recurrence in 83% of cases when the medication was
stopped. Those with recurrence (n = 10) re-started IFX in a dose optimization study in which we showed that
3 mg/Kg were sufficient to re-induce and maintain endoscopic remission for 1 year in all patients (ref.2). Five
of these ten patients participated in the current study. Antibodies To Infliximab [ATI] and Infliximab Trough
Levels [ITL] were measured and compared to those of CD patients who did not undergo surgery in remission
on a standard 5 mg/Kg IFX dose. After an additional 18 months the patients treated with 3 mg/Kg IFX
underwent colonoscopy.
doi:10.1371/journal.pone.0144900.g001
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Ethical considerations
The study was approved by the Ethical Committee of the University of Udine, Italy. Individuals
signed a proper informed consent before enrolment.
Statistical methods
The Student’s t test was used to compare infliximab concentrations, HS-CRP and FC levels in
study subjects and controls with the significance level set at 5%.
Results
Patient features
Table 1 illustrates the main features of the study subjects and controls. The 2 groups did not
differ in terms of sex distribution, age (mean±SE: 40.6±3.3 vs 35.5±5.1 years for study subjects
and controls respectively) and disease duration (7.6±1.8 vs 6.2±0.8 years). One patient per
group was actively smoking at time of enrolment.
Pharmacokinetics and markers of inflammation
After the infusion, as expected, infliximab concentrations followed first order kinetics in both
controls and study subjects with concentrations at any point in time being approximately half
in patients treated with 3 mg/Kg compared to controls (Fig 2A).
In all patients, falling infliximab levels were accompanied by increases in HS-CRP and FC
towards the end of the 8 week interval (Fig 2B and 2C).
At any point in time HS-CRP concentrations were higher in controls than in patients
treated with 3 mg/Kg (Fig 2B) the difference reaching statistical signaficance for the pre-infu-
sion values. Likewise, mean FC levels in controls were significantly higher than in study sub-
jects and above the upper limit of the normal range at midinterval and before the infusion (Fig
2C).
Table 1. Patient features at enrollment.
Patients Age/
Sex
Disease duration
(years)
Disease
location
Previous
surgery
Smoking
status
Inﬂiximab dose (mg/
Kg)
Treatment
duration
Study subjects
#1 51/M 8 Neo-TI Yes Yes 3 12 months
#2 40/F 11 Neo-TI Yes No 3 12 months
#3 44/M 12 Neo-Ti Yes No 3 12 months
#4 36/M 3 Neo-TI Yes No 3 12 months
#5 32/M 4 Neo-TI Yes No 3 12 months
Controls
#1C 29/M 6 TI + colon No Yes 5 16 months
#2C 43/M 5 TI No No 5 8 months
#3C 24/M 7 Left colon ﬁstula No 5 12 months
#4C 37/M 4 ileocecal No No 5 7 months
#5C 48/M 10 ileocecal No No 5 24 months
#6C 32/M 5 TI No No 5 14 months
doi:10.1371/journal.pone.0144900.t001
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ITL and ATI
Mean values ± SE of ITL were 4.75±0.83 μg/mL in controls as opposed to 2.0±0.3 μg/mL in
patients treated with infliximab 3 mg/Kg (p<0.05). In 4/5 patients treated with low dose
Fig 2. Infliximab concentration (A), Highly Sensitive [HS]–CRP (B) and Fecal Calprotectin (C) during
infliximab therapy. Empty long dash lines: control patients (treated with infliximab 5 mg/Kg); Filled lines:
study subjects (treated with infliximab 3 mg/Kg). Square dot lines indicate the upper limit of the normal range
for HS-CRP and Fecal Calprotectin. Values are reported as mean and standard error (vertical bars). The
asterisk denotes a significant difference (p < 0.05) between controls and study subjects at a given time point
during the 8-week therapeutic interval.
doi:10.1371/journal.pone.0144900.g002
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infliximab ITL were lower than 3 μg/mL (Table 2) whereas in all controls ITL were>3 μg/mL.
ATI were present in 2/5 patients treated with 3 mg/Kg and in none of the controls. In both
ATI-positive patients concentrations were below 10 U/mL (Table 2).
Clinical follow up and endoscopy
Follow up and endoscopy were undertaken in patients treated with low dose infliximab. After
18.6 ± 5.5 additional months of treatment with infliximab 3 mg/Kg all 5 patients were still in
full clinical remission (CDAI< 150). Colonoscopy revealed Rutgeers scores identical to base-
line (baseline: one year of treatment with low dose infliximab) and all within endoscopic remis-
sion (0,1,1,1,0) (Fig 3A–3E). No infusion reactions or infliximab-related side effects were
reported within the entire 30 month treatment period.
The additional 5 patients with POR treated for one year with infliximab 3 mg/Kg originally
included in the dose titration study (2) and not enrolled in the current study maintained clini-
cal remission (CDAI< 150) after an additional 12 months of clinical follow up.
Discussion
Since 2006 a number of studies have shown that anti-TNF agents are effective in preventing
POR in CD (reviewed in ref.1). However, long term management of these patients remains an
important issue due to costs and potential side effects of these medications [5–9]. Stopping
infliximab [10,11] might cause prompt endoscopic relapse [2] which in time might lead to clin-
ical recurrence [3]. Thus, this approach remains the subject of debate [5–9]. Since patients after
surgery might bear a low disease burden, we tested lower than standard doses of infliximab in
patients with proven endoscopic recurrence—previously maintained in remission with inflixi-
mab 5 mg/Kg. We have shown that a dose of 3 mg/kg every 8 weeks appears sufficient to
restore and maintain mucosal remission for 1 year in all the studied subjects [2].
However a low dose might lead to low ITL and formation of ATI—an event that could
potentially cause loss of response and/or infusion reactions [12–13]. However, it is unclear
whether the presence of ATI might affect the clinical outcome in all patients [14, 20, 21]. The
threshold ITL below which symptom relapse and inflammation might become more likely has
been reported to be 3 μg/mL [12,15]–a value partly dependent on the type of assay used [22].
Because there appears to be a close relationship between disease activity and ATI/ITL in CD
[16, 23], it has been proposed that a management strategy based on ATI/ITL measurements
might be more efficient and cost effective than one based on clinical parameters [24, 25].
To address these issues we have studied here the impact of ATI and ITL in a subgroup of
those patients in clinical (CDAI<150) and endoscopic (Rutgeerts score 0–1) remission after
12 months of therapy with infliximab 3 mg/Kg. In addition to ITL and ATI, putative markers
of disease activity/inflammation—HS-CRP and FC—were also measured during the 8-week
therapeutic interval. For comparison purposes ITL, ATI and inflammatory markers in the
study subjects were contrasted to those of control patients—i.e. CD patients maintained in clin-
ical remission (CDAI<150) with infliximab 5 mg/Kg.
In both controls and study subjects the levels of the inflammatory markers appeared in a
dynamic balance with infliximab concentrations throughout the 8-week interval. FC and
HS-CRP appeared on the average higher in controls than in study subjects at any time point,
suggesting a tighter control of inflammation in the latter.
ITL were detectable in all patients treated with infliximab 3 mg/Kg but were below the hypo-
thetical therapeutic threshold of 3 μg/ml in 4 out of 5 patients. By contrast and as expected, ITL
were greater than 3 μg/ml in all the controls. Low levels ATI were detected in 2 out of 5 patients
treated with low infliximab doses, while being absent in all the controls. Patients on low dose
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infliximab continued such treatment and underwent colonoscopy after 18 additional months
of therapy on the average. Colonoscopy was unchanged compared to baseline—i.e. all patients
remained in full endoscopic remission. Likewise, CDAI remained below 150 in all study sub-
jects after a total of 30 months of treatment. No infusion reactions or infliximab-related side
effects were recorded within the entire follow-up period.
Overall, these data show that an infliximab dose of 3 mg/kg appears sufficient to avoid
endoscopic and clinical POR in the long term. Our data also suggest that the threshold thera-
peutic ITL might be lower than 3 μg/ml in relapsing patients after surgery. In patients treated
with infliximab 3 mg/Kg, ATI levels—when present—were<10 U/mL, a concentration which
may not affect clinical outcomes [21,22] possibly because of their transient nature [21].
Our study has many obvious limitations, including the very small sample size and the mea-
surement of ATI during a limited period of time. In addition, this is the follow up of an original
study which was not blinded or randomized. Nevertheless, each patient was thoroughly studied
clinically, endoscopically and biochemically. Our study compared drug pharmacokinetics and
inflammatory markers of post-operative CD patients treated with low infliximab dose with
those of CD patients who did not undergo surgery in remission on 5 mg/Kg infliximab. It was
not an aim of this study to compare the clinical and endoscopic outcomes between the two dif-
ferent groups—which conceivably differed in terms of disease burden and therapeutic needs.
Rather, we included patients treated with the standard infliximab dose as an internal control—
since CD patients on 5 mg/Kg in full clinical remission have usually ITL> 3 μg/ml and are
ATI negative [12,15], findings confirmed by our study.
It is possible that low infliximab doses might also be able to control inflammation in a pro-
portion of CD patients who have not undergone surgery but bear a low disease burden like
those operated on. Clearly, the comparative effectiveness of such strategy in both groups would
need to be confirmed in a large study.
In conclusion, our small study provides objective support to the hypothesis that infliximab
doses as low as 3 mg/Kg might be effective in the long term to prevent disease recurrence in
Table 2. ITL and ATI in patients treated with infliximab 3 mg/Kg and controls.
Patient#1 Patient#2 Patient#3 Patient#4 Patient#5 Controls
ITL (μg/mL) 4.4±0.8 0.91±0.1 0.91±0.1 1.3±0.3 2.8±0.3 4.75 ±0.83
ATI (U/mL) Negative 5.4±0.3 Negative 7.7±0.8 Negative Negative
Individual patients ITL and ATI concentrations are the mean ± standard error of 3 consecutive 8-week therapeutic interval sample values measured
immediately before infusion. For the 6 controls, all data are pooled together and presented as mean± standard error. Individual samples were tested at
least in duplicate. ITL: Inﬂiximab Trough Levels. ATI: Antibodies To Inﬂiximab
doi:10.1371/journal.pone.0144900.t002
Fig 3. Endoscopy (neo-terminal ileum) after a total of 30 months of therapy with infliximab 3 mg/Kg.Rutgeerts scores were identical to baseline
(baseline: one year of treatment with infliximab 3 mg/Kg): 0,1,1,1,0 in patients #1,#2,#3,#4,#5 listed in Table 1, respectively (A-E).
doi:10.1371/journal.pone.0144900.g003
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patients undergone surgery for CD. For the time being, it is difficult to envision more efficient
long term strategies when using anti-TNF agents. As in CD patients who have not had surgery,
it is possible that a proportion of patients with POR on combination therapy might be kept in
clinical remission by stopping infliximab while maintaining the immunomodulator [10]. In
such case, it would remain to be seen whether the addition of an immunomodulator to anti-
TNF agents in the postoperative setting would bear clear advantages to justify the known risk
of side effects in patients exposed to combination therapy [26].
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